Loading…
Employees: 1,306
Size DongKook Pharmaceutical (086450.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $776M, the 272nd largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩23,550 on 6 Nov 2026.
Performance Over six months the shares fell 1.5%, against -10.9% for the median peer and -24.5% for the South Korea market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 12.7% over the last twelve months (peer median +2.0%); the operating margin is 10.5% (peer median 6.4%).
Valuation It trades at 12.4× forward earnings against a peer median of 19.9× (3rd cheapest of 8).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.5 points above its cost of capital (5.4% WACC).
Next results Next results expected around 13 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩980B | ₩927B | ₩812B | ₩731B | ₩662B |
| Revenue growth | — | +14% | +11% | +10% | — |
| Gross profit | ₩532B | ₩492B | ₩440B | ₩405B | ₩375B |
| EBITDA | ₩136B | ₩128B | ₩108B | ₩88.0B | ₩91.4B |
| Net income | ₩76.3B | ₩66.0B | ₩61.2B | ₩47.2B | ₩52.9B |
| Free cash flow | ₩37.4B | ₩29.5B | ₩50.9B | ₩9.64B | ₩1.99B |
| Capital expenditure | ₩59.0B | ₩46.0B | ₩30.8B | ₩39.4B | ₩51.2B |
| Total debt | ₩67.3B | ₩76.2B | ₩80.7B | ₩105B | ₩91.4B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 086450.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.7% | -3.6% | 7th highest of 20 |
| 6-month return | -1.5% | -10.9% | 5th highest of 20 |
| Distance from 52-week high | -24.6% | -33.6% | 4th highest of 20 |
| Revenue growth (TTM) | +12.7% | +2.0% | 5th highest of 19 |
| Operating margin | 10.5% | 6.4% | 7th highest of 19 |
| Forward P/E | 12.4× | 19.9× | 3rd cheapest of 8 |
| Growth the price implies (Req g, 7 yrs) | -6.3% | 7.2% | 2nd least demanding of 13 |
| Growth delivered (Del g) | +10.6% | +3.7% | 6th highest of 13 |
| Hurdle (Req g minus delivered) | -16.9 pp | -0.4 pp | 3rd least demanding of 13 |
| ROIC minus cost of capital | +3.5 pp | -1.7 pp | 5th highest of 18 |
| EV / EBITDA | 8.1× | 11.4× | 3rd cheapest of 9 |
| Net debt / EBITDA | -0.4× | -0.7× | 4th most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| DongKook Pharmaceutical 086450.KS | South Korea | $776M | -1% | +13% | 10% | 12.4× | -6.3% | +10.6% |
| Youcare Pharmaceutical 688658.SS | China | $776M | -41% | -7% | -13% | 28.8× | n/a | n/a |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $777M | -8% | +9% | 24% | 11.9× | 11.5% | +11.3% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $771M | -29% | -16% | 0% | n/a | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | n/a | -1.4% | 0.0% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 3.4× | -7.0% | +20.3% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 17.8× | -1.1% | +26.1% |
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | n/a | 0.2% | +0.5% |
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | n/a | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | n/a | n/a | n/a |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $753M | -11% | +4% | 2% | n/a | 4.9% | +5.3% |
| Sanofi India SANOFI.NS | India | $800M | -3% | -6% | 26% | 19.9× | 16.5% | -8.7% |
| Knight Therapeutics GUD.TO | Canada | $800M | +37% | +42% | 5% | 76.4× | 9.5% | +17.7% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $801M | -19% | -6% | 10% | n/a | 18.2% | +2.1% |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | n/a | n/a | n/a |
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | n/a | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | n/a | -3.0% | -0.8% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | n/a | 10.7% | -1.4% |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $743M | -32% | +7% | 8% | 123.9× | 33.8% | +19.8% |